Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02345850 · ClinicalTrials.gov registry record · Phase 3
Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Phase 3 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 3
- Development phase
- 346
- Enrollment target
NCT02345850 is a Phase 3 study that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 346 participants.
The verdict
NCT02345850, a Phase 3 study, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 346 participants
- Enrollment target
Study Summary
The study is designed as a three arm randomized Phase III, multicenter trial comparing two calcineurin inhibitor (CNI)-free strategies for Graft-versus-Host Disease (GVHD) prophylaxis to standard tacrolimus and methotrexate (Tac/Mtx) in patients with hematologic malignancies undergoing myeloablative conditioning hematopoietic stem cell transplantation.
Interventions
- DRUG Cyclophosphamide
- DRUG Tacrolimus
- PROCEDURE Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate
- PROCEDURE Mobilized CD34-selected Peripheral Blood Stem Cell graft
- PROCEDURE Unmanipulated Bone Marrow Graft with Cyclophosphamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2015-08 |
| Est. Completion | 2020-10-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02345850
The ClinicalTrials.gov registry entry for NCT02345850 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 346 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02345850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02345850 about?
NCT02345850 is a clinical study titled "Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)". The study is designed as a three arm randomized Phase III, multicenter trial comparing two calcineurin inhibitor (CNI)-free strategies for Graft-versus-Host Disease (GVHD) prophylaxis to standard tacrolimus and methotrexate (Tac/Mtx) in patients with hematologic malignancies undergoing myeloablative...
What is the current status of trial NCT02345850?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 346 participants. The study started on 2015-08. Estimated completion is 2020-10-05.
What interventions are being tested in trial NCT02345850?
The interventions under investigation include: Cyclophosphamide (DRUG), Tacrolimus (DRUG), Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate (PROCEDURE), Mobilized CD34-selected Peripheral Blood Stem Cell graft (PROCEDURE), Unmanipulated Bone Marrow Graft with Cyclophosphamide (PROCEDURE).
Who is sponsoring clinical trial NCT02345850?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.